FDAnews Drug Daily Bulletin

Xoma Lands Orphan Drug Status for Eye Disease Treatment

Aug. 24, 2012
Xoma lead drug, gevokizumab, was granted orphan drug status for an inflammatory eye disease. Gevokizumab, or XOMA-052, is a monoclonal antibody that focuses on shutting down inflammation brought on by a type of cell-signaling protein called interleukin-1 beta.
San Francisco Business Journal